Pharmaceutical companies at SABCS 2026

Dec 8–11, 2026 San Antonio, TX ~11k attendees Website

18 pharmaceutical companies are at SABCS 2026 — 27 presentations on the program and 14 with a booth in the exhibit hall. Most represented: AstraZeneca (6 on the program), Genentech (3 on the program), Gilead Sciences (3 on the program). 14 of them have their own page in this guide. As of Nov 10, 2026.

All 956 organizations at SABCS 2026 →

Focus
Top represented
Showing 1–12 of 18 organizations
OrganizationSABCS 2026 Attendance
AstraZeneca
Cambridge, UK
Pharma
Global drugmaker whose breast cancer medicines include HER2- and TROP2-directed antibody-drug conjugates and treatments for hormone receptor-positive disease.
Booth
Exhibiting at Booth 624
Wed, Dec 912:00pm–6:30pmThu, Dec 1012:00pm–6:30pmFri, Dec 1112:00pm–3:00pm
Poster
Thu Dec 10
12:30–2pm
Multimodal Foundation Models Unlock Transcriptomic Subtypes from Routine H&E Slides in TNBC
Exhibit Hall
Artificial Intelligence, Computational Biology, and Systems Biology
Genentech
South San Francisco, CA
Pharma
Roche Group biotechnology company whose breast cancer medicines include HER2-targeted antibodies and treatments for hormone receptor-positive disease.
Booth
Exhibiting at Booth 125
Wed, Dec 912:00pm–6:30pmThu, Dec 1012:00pm–6:30pmFri, Dec 1112:00pm–3:00pm
Poster
Wed Dec 9
12:30–2pm
Poster
Thu Dec 10
12:30–2pm
Gilead Sciences
Foster City, CA
Pharma
Biopharma company whose cancer portfolio spans antibody-drug conjugates, small molecules and, through Kite, cell therapies.
Booth
Exhibiting at Booth 608
Wed, Dec 912:00pm–6:30pmThu, Dec 1012:00pm–6:30pmFri, Dec 1112:00pm–3:00pm
Poster
Thu Dec 10
12:30–2pm
Narrowing Black-White Disparities and Reducing Late-Stage Breast Cancer Diagnosis Through Patient Navigation in Underserved Communities
Exhibit Hall
Policy, Access to Care, Health Outcomes and Cancer Care Delivery
Poster
Thu Dec 10
12:30–2pm
Merck & Co.
Rahway, NJ
Pharma
Global drugmaker with one of the largest oncology development programs, spanning more than 30 tumor types, including immunotherapy for triple-negative breast cancer.
Booth
Exhibiting at Booth 1108
Wed, Dec 912:00pm–6:30pmThu, Dec 1012:00pm–6:30pmFri, Dec 1112:00pm–3:00pm
Poster
Wed Dec 9
5–6:30pm
Jazz Pharmaceuticals
Dublin, Ireland
Pharma
Global biopharma company with medicines for serious diseases, including zanidatamab, a HER2-targeted bispecific antibody studied in breast cancer.
Booth
Exhibiting at Booth 1642
Wed, Dec 912:00pm–6:30pmThu, Dec 1012:00pm–6:30pmFri, Dec 1112:00pm–3:00pm
Poster
Thu Dec 10
12:30–2pm
Pfizer
New York, NY
Pharma
Global drugmaker whose breast cancer medicines include treatments for hormone receptor-positive and HER2-positive disease.
Booth
Exhibiting at Booth 1124 · Pfizer Oncology
Wed, Dec 912:00pm–6:30pmThu, Dec 1012:00pm–6:30pmFri, Dec 1112:00pm–3:00pm
Daiichi Sankyo
Tokyo, Japan
Pharma
Japanese drugmaker whose oncology portfolio centers on antibody-drug conjugates, including HER2- and TROP2-directed treatments used in breast cancer.
Booth
Exhibiting at Booth 343
Wed, Dec 912:00pm–6:30pmThu, Dec 1012:00pm–6:30pmFri, Dec 1112:00pm–3:00pm
Poster
Fri Dec 11
12:30–2pm
Real-world treatment patterns in patients with high-risk HER2+ eBC in the United States
Exhibit Hall
Real-World Data and Real-World Evidence
Pharma
Global biopharma company developing medicines in oncology, hematology, immunology, cardiovascular disease and neuroscience.
Booth
Exhibiting at Booth 151
Wed, Dec 912:00pm–6:30pmThu, Dec 1012:00pm–6:30pmFri, Dec 1112:00pm–3:00pm
Poster
Wed Dec 9
12:30–2pm
BeOne Medicines
Basel, Switzerland
Pharma
Global oncology company developing and selling treatments for blood cancers and solid tumors, aiming for wider and more affordable access.
Booth
Exhibiting at Booth 1543
Wed, Dec 912:00pm–6:30pmThu, Dec 1012:00pm–6:30pmFri, Dec 1112:00pm–3:00pm
Eli Lilly and Company
Indianapolis, IN
Pharma
Global drugmaker whose cancer medicines include treatments for hormone receptor-positive breast cancer.
Booth
Exhibiting at Booth 324
Wed, Dec 912:00pm–6:30pmThu, Dec 1012:00pm–6:30pmFri, Dec 1112:00pm–3:00pm
Menarini-Stemline
New York, NY
Pharma
Oncology company in the Menarini Group that markets elacestrant (Orserdu) for ESR1-mutated, ER+/HER2- advanced breast cancer.
Booth
Exhibiting at Booth 309
Wed, Dec 912:00pm–6:30pmThu, Dec 1012:00pm–6:30pmFri, Dec 1112:00pm–3:00pm
Novartis
Basel, Switzerland
Pharma
Swiss drugmaker whose breast cancer medicines include treatments for hormone receptor-positive disease.
Booth
Exhibiting at Booth 643, 1142
Wed, Dec 912:00pm–6:30pmThu, Dec 1012:00pm–6:30pmFri, Dec 1112:00pm–3:00pm

Explore the full SABCS 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in San Antonio. Leave your work email and we’ll be in touch.

Privacy

Download the full SABCS 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Find buyers from pharmaceutical companies

Tell us what you sell and we’ll find the people at these pharmaceutical companies most likely to buy it.

  • Who to contact
  • Their contact info
  • What to say
  • Free, no sign-up

Browse SABCS 2026 by

Exhibit hall

Not affiliated with the San Antonio Breast Cancer Symposium, UT Health San Antonio or the American Association for Cancer Research. Organization details are derived from SABCS’s published program and exhibitor list. Submit a correction